上海盟科药业股份有限公司 审计报告及财务报表 二〇二四年度 上海盟科药业股份有限公司 审计报告及财务报表 （2024 年 01 月 01 日至 2024 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-13 | | | 财务报表附注 | 1-93 | 审计报告 信会师报字[2025]第 ZA10177 号 上海盟科药业股份有限公司全体股东： 一、审计意见 我们审计了上海盟科药业股份有限公司（以下简称盟科药业）财 务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公 司股东权益变动表以及相关财务报表附注。 | 关键审计事项 | 该事项在审计中是如何应对的 | | --- | --- ...

公司代码：688373 公司简称：盟科药业 上海盟科药业股份有限公司 2024 年度内部控制评价报告 上海盟科药业股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能 ...

关于上海盟科药业股份有限公司 2024 年度募集资金存放与使用情况 专项报告的鉴证报告 页 次 | | 证报告 | | | | --- | --- | --- | --- | | 一、 二、 | 2024 2024 | 年度募集资金存放与使用情况专项报告的鉴 年度募集资金存放与使用情况专项报告 | 1-2 1-11 | 关于上海盟科药业股份有限公司 2024年度募集资金存放与使用情况专项报告的鉴证报告 信会师报字[2025]第ZA10180号 上海盟科药业股份有限公司全体股东： 我们接受委托，对后附的上海盟科药业股份有限公司（以下简 称 "盟科药业"）2024年度募集资金存放与使用情况专项报告（以下 简称 "募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 盟科药业董事会的责任是按照中国证券监督管理委员会《上市 公 司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》（证监会公告〔2022〕15号）、《上海证券交易 所 科创板上市公司自律监管指引第1号——规范运作》（2023年12 月修 订）以及《上海证券交易所上市公司自律监管指南第1号—— 公告格 式》的相关规定编 ...

证券代码：688373 证券简称：盟科药业 公告编号：2025-011 上海盟科药业股份有限公司 第二届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 上海盟科药业股份有限公司（以下简称"公司"）第二届监事会第十次会 议（以下简称"本次会议"）于2025年3月17日在公司会议室，通过现场表决与 通讯表决相结合的方式召开。本次会议通知及相关资料已于2025年3月6日通过 邮件送达全体监事。本次会议应出席监事3人，实际出席监事3人。本次会议由 监事会主席卢亮先生召集并主持。本次会议的召集和召开符合《中华人民共和 国公司法》等相关法律、行政法规、规范性文件和《上海盟科药业股份有限公 司章程》（以下简称"《公司章程》"）的规定，会议形成的决议合法、有效。 二、 监事会会议审议情况 (一)审议通过《关于<公司2024年年度报告及其摘要>的议案》 经审议，监事会认为：公司2024年年度报告编制和审议程序符合法律法规、 《公司章程》和公司内部管理制度的各项规定；报告内容真实、准确、完整 ...

Financial Performance - The company reported a net profit attributable to the parent company of negative value, indicating it has not yet achieved profitability[5]. - The company plans not to distribute cash dividends, issue bonus shares, or increase capital reserves for the 2024 fiscal year[9]. - In 2024, the company's operating revenue reached CNY 130.27 million, a year-on-year increase of 43.51%, primarily driven by the sales growth of its self-developed product, Contizole Tablets[30]. - The net loss attributable to shareholders increased by CNY 19.60 million, while the net loss after deducting non-recurring gains and losses increased by CNY 5.17 million compared to the previous year[30]. - Basic earnings per share for 2024 were -CNY 0.67, and the diluted earnings per share were also -CNY 0.67[29]. - The company reported a significant increase in revenue, achieving a total of 2.19 billion in sales for the year[85]. - The company has received a standard unqualified audit report from its accounting firm, ensuring the accuracy of its financial statements[7]. - The company has increased its sales expenses due to expanded academic promotion and distribution network efforts since the commercialization of Contizolam tablets[188]. Research and Development - The company has incurred significant research and development expenses, leading to cumulative losses that continue to increase[6]. - The company is focused on developing innovative drugs for infectious diseases, which typically require long development cycles and substantial investment[5]. - The company continues to enhance its core competitiveness by enriching its new drug pipeline, with multiple innovative drugs in critical clinical trial stages[30]. - The company maintains a high level of overall R&D investment to support ongoing projects[30]. - The R&D expenditure as a percentage of operating revenue was 282.92%, a decrease of 96.98 percentage points compared to the previous year[29]. - The company has established a comprehensive antibacterial new drug R&D system, covering the entire process from early design to clinical development and production management[184]. - The total R&D investment for the year was approximately ¥368.56 million, representing a 6.87% increase from the previous year[178]. - The company has filed 33 new patent applications this year, bringing the total number of applications to 82[175]. Product Development and Pipeline - The core product, Kangtaizuoan tablets, has been launched, with multiple other products in clinical trials both domestically and internationally[5]. - The company has one marketed drug, four drugs in clinical stages, and multiple drugs in preclinical research, indicating a robust R&D pipeline[186]. - The company is actively advancing the development of MRX-8 for resistant Gram-negative bacterial infections, with the Phase I clinical trial in China successfully completed[46]. - The company has initiated a Phase II clinical trial for oral Contizolam tablets in treating complex skin and soft tissue infections in children aged 6 to 17, with 12 centers obtaining ethical approval[45]. - The international multi-center Phase III clinical trial for injectable MRX-4 has been approved in nearly 20 countries, with 324 patients enrolled[46]. - The company is exploring a full oral treatment strategy including MRX-5 for patients with NTM infections, aiming for safer and more effective treatment options[48]. - The company is focused on expanding its market presence and enhancing its product offerings through innovative research and development initiatives[54]. Market and Competitive Landscape - The overall business performance is maintaining a good growth trend, supported by continuous innovation and market demand[41]. - The company is committed to developing core competencies in drug discovery and targeting unmet clinical needs, with a focus on both domestic and international markets[41]. - The company is focusing on expanding its product line with new antibiotics targeting resistant strains, which is expected to enhance market competitiveness[85]. - The company aims to expand potential indications for MRX-4 by initiating a Phase III clinical trial for treating resistant Gram-positive bacterial infections[63]. - The company is leveraging its existing products to deepen its engagement in the antibiotic market, particularly for multi-drug resistant infections[160]. Risks and Challenges - The company emphasizes the risks associated with its ongoing research and development activities, which may affect future profitability[6]. - The company faces risks related to clinical trial progress, potential failures, and regulatory approvals for its pipeline products[192]. - The company has no independent production capability and relies on a single supplier, which poses a risk of supply shortages[194]. - The company is currently unprofitable, which may impact its ability to sustain R&D investments and operational stability[189]. Antimicrobial Resistance - The focus on antimicrobial resistance highlights the importance of developing new antibiotics to combat resistant strains, a key area of research for the company[74]. - The company is focused on developing new antimicrobial drugs and diagnostic tools to combat the global resistance issue, as highlighted by the World Health Organization's global action plan[77]. - The company recognizes the urgent need for investment in new drugs, vaccines, and diagnostic tools to optimize the use of existing antimicrobials and combat resistance[77]. - The company is committed to addressing the challenges posed by bacterial infections, which can spread through various transmission routes, including contact and airborne methods[78]. Clinical Trials and Approvals - The company is advancing its MRX-1 and MRX-4 candidates into Phase III clinical trials for the treatment of multi-drug resistant Gram-positive infections[132]. - The FDA has declined approval for Solithromycin and Iclaprim, while Levonadifloxacin is in Phase III trials and expected to be the first approved treatment for Gram-positive multi-drug infections[132]. - The company has received approval from the National Medical Products Administration to conduct clinical trials for MRX-5 tablets in China[67]. Strategic Initiatives - The company is exploring potential mergers and acquisitions to bolster its research and development capabilities and expand its product portfolio[85]. - The company is actively participating in national medical insurance negotiations to improve product accessibility for patients[73]. - A new strategic partnership has been established to enhance distribution channels, aiming to improve product availability in key markets[85].

证券代码：688373 证券简称：盟科药业 公告编号：2025-008 上海盟科药业股份有限公司 关于自愿披露美国子公司提起诉讼的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 本次诉讼事项受理的基本情况 公司全资子公司盟科美国于北京时间2025年2月24日收到美国俄亥俄州南区 联邦地区法院西部分院起诉立案确认通知，盟科美国诉Medpace, Inc.（以下简称 "Medpace"）合同纠纷一案已完成起诉立案。 截至本公告披露日，上述案件尚未开庭审理。 二、 本次诉讼的基本情况 1、原告：盟科美国 1、案件所处的诉讼阶段：法院已立案，尚未开庭审理。 2、上市公司所处的当事人地位：上海盟科药业股份有限公司（以下简称" 公司"）的全资子公司MicuRx Pharmaceuticals, Inc.（以下简称"盟科美 国"）为原告 3、涉案的金额：盟科美国提起的诉讼申请暂未提及具体金额，需以法院判 决或执行结果为准 4、是否会对上市公司损益产生负面影响：截至本公告披露日，本次诉讼尚 未开庭审理，最终实际 ...

Financial Performance - In 2024, the company achieved total operating revenue of RMB 130.27 million, a year-on-year increase of 43.51%[4] - The net profit attributable to the parent company was a loss of RMB 440.72 million, an increase in loss of RMB 19.60 million compared to the previous year[7] - Total assets at the end of 2024 were RMB 849.13 million, a decrease of 27.34% year-on-year[8] - The equity attributable to the parent company decreased by 47.37% year-on-year, amounting to RMB 438.96 million[5] - The basic earnings per share were -0.67 RMB, compared to -0.64 RMB in the previous year[4] - The net asset per share attributable to the parent company was 0.67 RMB, down 47.24% year-on-year[5] Research and Development - The company increased its investment in R&D, leading to higher R&D expenses during the reporting period[9] - The company continues to promote key R&D projects and actively market its core product, resulting in sustained high levels of loss[12] Business Growth - The increase in hospital coverage and prescription volume contributed to steady growth in main business revenue[12] Reporting Accuracy - There are no significant uncertainties affecting the accuracy of the performance report[13]

Revenue Projections - The company expects 2024 annual revenue to be approximately between 120 million and 140 million CNY, an increase of 29.22 million to 49.22 million CNY compared to the previous year, representing a growth of 32.19% to 54.23% year-on-year[3]. - The previous year's revenue was 90.78 million CNY[5]. Net Loss Projections - The projected net loss attributable to the parent company for 2024 is expected to be between 480 million and 440 million CNY, an increase in loss of 18.88 million to 58.88 million CNY compared to the previous year, reflecting a year-on-year increase in loss of 4.48% to 13.98%[3]. - The expected net loss attributable to the parent company after deducting non-recurring gains and losses for 2024 is projected to be between 500 million and 460 million CNY, an increase in loss of 5.99 million to 45.99 million CNY compared to the previous year, indicating a year-on-year increase in loss of 1.32% to 10.13%[3]. - The previous year's net loss attributable to shareholders was 421.12 million CNY[6]. Business Growth Factors - The increase in main business revenue is attributed to the growth in the number of hospitals covered and the increase in prescription volume[8]. Expenses and Losses - The continued losses are primarily due to increased R&D expenses as clinical projects progress and higher sales expenses due to active sales efforts[9]. Financial Data and Risks - The financial data in this forecast has not been audited by registered accountants[4]. - The forecast data is preliminary and the accurate financial data will be disclosed in the audited 2024 annual report[11]. - Investors are advised to pay attention to investment risks related to the preliminary nature of the forecast data[11].

证券代码：688373 证券简称：盟科药业 公告编号：2025-004 上海盟科药业股份有限公司 第二届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 董事会会议召开情况 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的 《上海盟科药业股份有限公司关于2023年限制性股票激励计划首次授予部分第 一个归属期符合归属条件的公告》（公告编号：2025-002）。 （二）审议通过《关于作废部分已授予尚未归属的限制性股票的议案》 根据《激励计划》和《考核管理办法》的相关规定及公司2022年年度股东 大会对董事会的授权，由于《激励计划》项下首次授予的24名激励对象因个人 原因离职，不再具备激励对象资格；54名激励对象自愿放弃或部分放弃本次归 属；3名激励对象2023年度个人考核评价结果为"C"，其在本次归属项下对应 的个人考核层面的归属系数为50%；本次归属公司考核指标层面的归属系数为 75%，董事会决定相应作废公司2023年限制性股票激励计划中部分已授予尚未 归属的限制 ...

属名单的核查意见 2025 年 1 月 7 日 依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办 法》、《上海证券交易所科创板股票上市规则》等相关法律、法规及规范性文 件和《上海盟科药业股份有限公司章程》的有关规定对公司 2023 年限制性股票 激励计划（以下简称"本次激励计划"）首次授予激励对象第一个归属期归属 名单进行审核，监事会发表核查意见如下： 上海盟科药业股份有限公司监事会 上海盟科药业股份有限公司 关于 2023 年限制性股票激励计划首次授予部分第一个归属期归 监事会 本次激励计划授予的激励对象共 119 名，除 24 名激励对象因离职丧失激励 对象资格不符合归属条件，54 名激励对象因个人原因放弃或部分放弃参与本次 归属外，公司 2023 年限制性股票激励计划首次授予部分第一个归属期可归属的 47 名激励对象符合《公司法》《证券法》等法律、法规和规范性文件规定的激 励对象条件，符合本次激励计划规定的激励对象范围，其作为公司本次限制性 股票激励计划首次授予激励对象的主体资格合法、有效，激励对象获授限制性 股票的第 ...